Synthesis and in vitro evaluation of substituted phenyl-piperazinyl-phenyl oxazolidinones against gram-positive bacteria

Chemical Biology and Drug Design

Volumn 69, Issue 4, 2007, Pages 265-268

  Liu, Jidong ^a,b   He, Baoyuan ^a   Yu, Aizhen ^a   Zhou, Weicheng ^a  

^a SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Anti bacterial agents; Gram positive bacteria; Linezolid; Multi drug resistance; Oxazolidinone; Piperizine

Indexed keywords

3 [4' (2 METHOXYLPHENYL)PIPERAZINYL] 3' FLUOROPHENYL 5 ACETYLAMINOMETHYLOXAZOLIDINONE; 3 [4' (4 METHOXYLPHENYL)PIPERAZINYL] 3' FLUOROPHENYL 5 ACETYLAMINOMETHYLOXAZOLIDINONE; OXAZOLIDINONE DERIVATIVE; PHENYL GROUP; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS ALBUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS ENTERIDIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; MOLECULAR STRUCTURE; OXAZOLIDINONES; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; STREPTOCOCCUS ALBUS; STREPTOCOCCUS PNEUMONIAE;

EID: 34247531230     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00498.x     Document Type: Article

References (24)

1. Spera Jr. R.V., Farber B.F. (1994) Multidrug-resistant Enterococcus faecium an untreatable nosocomial pathogen. Drugs : 48 : 678 688.
2. Tomasz A. (1994) Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. N Engl J Med 330 : 1247 1251.
3. Fekete T. (1995) Bacterial genetics, antibiotic usage, and public policy: The crucial interplay in emerging resistance. Perspect Biol Med 38 : 363 382.
4. Courvalin P. (1994) Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 38 : 1447 1451.
5. Boyce J.M., Opal S.M., Chow J.W., Zervos M.J., Potter-Bynoe G., Sherman C.B., Romulo R.L., Fortna S., Medeiros A.A. (1994) Outbreak of multidrug-resistant Enterococus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 32 : 1148 1153.
6. Perry C. M., Jarvis B. (2001) A review of its use in the management of serious gram-positive infections. Drugs 61 : 525 551.
7. Eustice D.C., Feldman P.A., Slee A.M. (1988) The mechanism of action of Dup 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem Biophys Res Commun 150 : 965 971.
8. Eustice D.C., Feldman P.A., Zajac I., Slee A.M. (1988) Mechanism of action of Dup 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 32 : 1218 1222.
9. Johnson A.P., Tysall L., Stockdale M.V., Woodford N., Kaufmann M.E., Warner M., Livermore D. M., Asboth F., Allerberger F.J. (2002) Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbial Infect Dis 21 : 751 754.
10. Auckland C., Teare L., Cooke F., Kaufmann M. E., Warner M., Jones G., Bamford K., Ayles H., Johnson A.P. (2002) Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50 : 743 746.
11. Tsiodras S., Gold H. S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., Ferraro M.J. (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 : 207 208.
12. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., Robbins M. (2003) Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51 : 186 188.
13. Park C.H., Brittelli D.R., Wang C.L.J., Marsh F.D., Gregory W.A., Wuonola M.A., McRipley R.J., Eberly V.S., Slee A.M., Forbes M. (1992) Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives. J Med Chem 35 : 1156 1165.
14. Betts M.J., Darbyshire C.J 1998) WO Patent 9801447.
15. Betts M.J., Darbyshire C.J. (1998) WO Patent 9801446.
16. Cui Y., Yang Y., Chen K., Ji R., Zhang S. (2003) Synthesis and antibacterial activity of oxazolidinone containing sulfonyl group. Bioorg Med Chem Lett 13 : 2311 2313.
17. Du Y., Guo H. (2002) Synthesis and antibacterial activity of linezolid analogues. Bioorg Med Chem Lett 12 : 857 859.
18. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., Zurenko G.E. (1996) Synthesis and antibacterial activity of U-100593 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 39 : 673 679.
19. Grega K.C., Barbachyn M.R., Brickner S.J., Mizsak S.A. (1995) Regioselective metalation of fluoroanilines. An application to the synthesis of fluorinated oxazolidinone antibacterial agents. J Org Chem 60 : 5255 5261.
20. Wang C.L.J., Gregory W.A., Wuonola M.A. (1989) Chiral synthesis of Dup 721, a new antibacterial agent. Tetrahedron 45 : 1323 1326.
21. Gololobov Y.G., Zhmurova I.N., Kasukhin L.F. (1981) Sixty years of staudinger reaction. Tetrahedron 37 : 437 472.
22. Andrews J.M. (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(S1) : 5 16.
23. Zhang Z., Zhou W., Yu A. (2004) Synthesis and antibacterial activity of 7-(substituted) aminomethyl quinolones. Bioorg Med Chem Lett 14 : 393 395.
24. Bartel S., Raddatz S., Haerter M., Rosentreter U., Wild H., Endermann R., Kroll H. (2000) DE Patent 19905278.